BRAF inhibitor Braftovi approved by the European Medicines Agency for the treatment of colorectal cancer in conjunction with EGFR antibody Erbitux
Last Update: 2020-06-16
Search more information of high quality chemicals, good prices and reliable suppliers, visit
The BRAF inhibitor Braftovi (encorafenib) and EGFR-targeted antibody Erbitux (cetuximab) were approved by the European Medicines Agency for use as a second-line treatment for patients previously undergoing systemic therapy and BRAF-positive colorectal cancerBraftovi was approved for same-adaptive disorders in the United States in AprilBraftovi has been approved to work with MEK inhibitor Mektovi (binimetinib) for the treatment of BRAF plus melanoma, a skin cancer, and analysts at Evaluate Pharma believe the drug will account for more than $700 million of total global sales of $1.2 billion for colorectal cancer by 2024Clinical results showed that Braftovi/Erbitux increased total survival (OS) by 40% compared to erbitux and Iliticon-based chemotherapy, with a median OS? 5.9 months and 9.3 months, respectivelyData from the trial also showed that combination therapy between the two drugs was as effective as triple therapy, including Mektovi, which meant that additional toxicity from MEK inhibitors could be avoided without harming patient healthColorectal cancer is the third most common cancer, with about 1.8 million new patients worldwide each year, 7-10% of whom have BRAF mutations
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.